NASDAQ$TMDX
TransMedics Group Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
TransMedics reported financial results for the first quarter of 2021.
TransMedics Group, Inc. reported a net revenue of $7.1 million for the first quarter of 2021, a 6% decrease compared to the first quarter of 2020. U.S. net revenue increased by 11% year-over-year. The gross margin was 68% as compared to 65% in the first quarter of 2020. Net loss for the first quarter of 2021 was $7.9 million compared to $8.9 million in the first quarter of 2020.
- Net revenue of $7.1 million in the first quarter of 2021, representing a 6% decrease compared to the first quarter of 2020.
- Reported U.S. net revenue growth of 11% year-over-year.
- Announced positive FDA advisory committee vote for OCS Heart System.
- Announced expectation for mid-July 2021 OCS Liver FDA advisory committee meeting.
Headline financials
Revenue & EPS history
TransMedics · Revenue · Quarterly
$7.05M
Forward guidance
The company is advancing quickly toward several near term regulatory and commercial catalysts expected in 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+4.1%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.6%
Avg return
30 days after
54%
15 / 28 earnings
Positive
+42.6%
Q3 2023
Best reaction
-29.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.1% | -30.0% | -26.4% | |
| Q4 2025 | -4.6% | -3.6% | -35.1% | |
| Q3 2025 | +0.9% | -9.0% | +8.9% | |
| Q1 2025 | +19.6% | +31.3% | +49.2% | |
| Q4 2024 | +5.8% | -6.5% | -4.9% | |
| Q3 2024 | -29.3% | -34.2% | -30.4% | |
| Q2 2024 | +9.4% | +7.2% | +21.4% | |
| Q1 2024 | +20.9% | +31.6% | +40.3% | |
| Q4 2023 | +6.7% | -0.5% | -10.8% | |
| Q3 2023 | +42.6% | +34.6% | +73.5% | |
| Q2 2023 | -8.9% | -24.7% | -21.5% | |
| Q1 2023 | -6.7% | -6.4% | -8.1% | |
| Q4 2022 | +20.2% | +20.4% | +15.4% | |
| Q3 2022 | +20.7% | +17.6% | +38.7% | |
| Q2 2022 | -7.7% | +20.8% | +28.9% | |
| Q1 2022 | +39.5% | +25.4% | +29.5% | |
| Q4 2021 | +23.2% | +39.5% | +82.5% | |
| Q3 2021 | -12.0% | -16.3% | -29.0% | |
| Q2 2021 | +9.6% | +7.6% | +17.2% | |
| Q1 2021 | -12.6% | -15.1% | -11.3% | |
| Q4 2020 | +3.4% | -12.3% | +10.6% | |
| Q3 2020 | +4.8% | +10.6% | +20.8% | |
| Q2 2020 | +0.1% | -3.2% | -11.9% | |
| Q1 2020 | -7.6% | -0.6% | -11.7% | |
| Q4 2019 | -1.1% | -1.2% | -25.7% | |
| Q3 2019 | -14.2% | -13.0% | -1.7% | |
| Q2 2019 | -4.2% | -4.6% | +8.6% | |
| Q1 2019 | -2.3% | -2.1% | -4.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro